ImmunityBio, Inc. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: +351.5%
EBITDA: —
EBIT: +16.6%
EPS: -55.2%
Free cash flow: +20.6%
Operating cash flow: +20.5%

Forward estimates

Revenue: +258.0%
EBITDA: +30.5%
EPS: +91.0%

Three-year CAGR

Revenue: +678.6%
EBITDA: +15.5%
EBIT: +25.6%
Net income: +15.0%
EPS: +35.6%
Free cash flow: +22.4%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.